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Adiponectin receptor-mediated signaling ameliorates
cerebral cell damage and regulates the neurogenesis of
neural stem cells at high glucose concentrations: an
in vivo and in vitro study
J Song1, SM Kang1,2, E Kim3, C-H Kim4, H-T Song5 and JE Lee*,1,2
In the central nervous system (CNS), hyperglycemia leads to neuronal damage and cognitive decline. Recent research has focused
on revealing alterations in the brain in hyperglycemia and finding therapeutic solutions for alleviating the hyperglycemia-induced
cognitive dysfunction. Adiponectin is a protein hormone with a major regulatory role in diabetes and obesity; however, its role in
the CNS has not been studied yet. Although the presence of adiponectin receptors has been reported in the CNS, adiponectin
receptor-mediated signaling in the CNS has not been investigated. In the present study, we investigated adiponectin receptor
(AdipoR)-mediated signaling in vivo using a high-fat diet and in vitro using neural stem cells (NSCs). We showed that AdipoR1
protects cell damage and synaptic dysfunction in the mouse brain in hyperglycemia. At high glucose concentrations in vitro,
AdipoR1 regulated the survival of NSCs through the p53/p21 pathway and the proliferation- and differentiation-related factors of
NSCs via tailless (TLX). Hence, we suggest that further investigations are necessary to understand the cerebral AdipoR1-mediated
signaling in hyperglycemic conditions, because the modulation of AdipoR1 might alleviate hyperglycemia-induced
neuropathogenesis.
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Adiponectin secreted by the adipose tissue1,2 exists in either a
full-length or globular form.3–6 Adiponectin can cross the
blood–brain barrier, and various forms of adiponectin are
found in the cerebrospinal fluid.7–11 Adiponectin exerts its
effect by binding to the adiponectin receptor 1 (AdipoR1) and
adiponectin receptor 2 (AdipoR2)12,13 that have different
affinities for the various circulating adiponectins.12,14–17
Several studies reported that both receptor subtypes are
expressed in the central nervous system (CNS).7,12,18
As adiponectin modulates insulin sensitivity and
inflammation,19 its deficiency induces insulin resistance and
glucose intolerance in animals fed a high-fat diet (HFD).19–21
In addition, adiponectin can ameliorate the glucose home-
ostasis and increase insulin sensitivity.22–24 Adiponectin,
which is the most well-known adipokine, acts mainly as an
anti-inflammatory regulator,25,26 and is associated with the
onset of neurological disorders.27 In addition, a recent study
reported that adiponectin promotes the proliferation of
hippocampal neural stem cells (NSCs).28 Considering that
adiponectin acts by binding to the adiponectin receptors,
investigation of the adiponectin receptor-mediated signaling in
the brain is crucial to understand the cerebral effects of
adiponectin and the underlying cellular mechanisms.
The prevalence of type II diabetes mellitus (DM2) and
Alzheimer’s disease increases with aging.29 According to a
cross-sectional study, in people with DM2, the risk of dementia
is 2.5 times higher than that in the normal population.30,31
A study performed between 1980 and 2002 suggested that an
elevated blood glucose level is associated with a greater risk
for dementia in elderly patients with DM2.32 In addition,
according to a 9-year-long longitudinal cohort study, the risk of
developing Alzheimer’s disease was 65% higher in people
with diabetes than in control subjects.33 A community-based
cohort study also reported that higher plasma glucose
concentrations are associated with an increased risk for
dementia, because the higher glucose level has detrimental
effects on the brain.31 High blood glucose level causes
mitochondria-dependent apoptosis,34–36 and aggravates
diverse neurological functions.37,38 Inflammation and oxida-
tive stress, which are commonly observed in people with
diabetes, inhibit neurogenesis.39–41 Similarly, neurogenesis is
decreased in mice and rats with genetically induced type I
diabetes.42,43 In addition, diabetic rodents have a decreased
proliferation rate of neural progenitors.43,44 Furthermore,
several studies suggested that an HFD leads to neuroin-
flammation, the impairment of synaptic plasticity, and cognitive
decline.45,46
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Here, we investigated whether AdipoR1-mediated signaling
is associated with cell death in the brain of mice on a HFD, and
whether high glucose level modifies the proliferation and
differentiation capacity of NSCs in vitro. Our study provides
novel findings about the role of AdipoR1-mediated signaling in
hyperglycemia-induced neuropathogenesis.
Results
HFD led to cell death in the mouse brain. To assess
the morphological alterations of neurons in mice fed a HFD,
we performed cresyl violet staining in the cortex and
striatum (Figure 1). In the control group, healthy round cells
were observed in these areas (Figure 1a). In the HFD group,
thin small cell bodies and damaged brain tissue were
visible in the cortex and striatum (Figure 1b). To identify
whether apoptotic cells were present in the brain tissues of
mice fed a HFD, we used the TdT-mediated dUTP nick
end labeling (TUNEL) assay47 (Figure 2). More TUNEL-
positive cells were observed in the cortex, striatum, and
hippocampus of mice fed a HFD than those in the brain
regions of the control mice (Figure 2). Our data suggest that
HFD damages cells in the cortex, striatum, and hippo-
campus (Figures 2a and b). In addition, we assume
colocalization with the NeuN, known as the marker of
neuron in TUNEL-positive cells (Figure 2c). Figure 2c
indicates that neuronal cells may be damaged in HFD brain
in comparison with the normal brain.
HFD decreased the expression of PSD95 and DCX in the
mouse brain. To determine the alterations caused by HFD
in a protein regulating synaptic plasticity and in a neuronal
microtubule-associated protein, we performed immunohisto-
chemistry using the antibodies specific for postsynaptic
density protein 95 (PSD95), a protein in the postsynaptic
density (Figure 3), and for doublecortin (DCX), a microtubule-
associated protein involved in neuronal migration (Figure 4).
The immunoreactivity for PSD95 synaptic density protein was
reduced in the mice fed a HFD compared with that in the
control group (Figure 3a). This result indicates that HFD
suppresses PSD95 expression in the striatum, cortex, and
hippocampus. Similarly, the protein level of PSD95 was
reduced in the HFD group (Figure 3b). To examine the
expression of the neuronal microtubule protein DCX, we
performed immunohistochemical (Figure 4a) and western
blot (Figures 4b and c) analyses. DCX immunoreactivity was
reduced in the brain of mice fed a HFD compared with that of
the control group (Figure 4a). Western blot revealed a similar
decrease in the protein level of DCX in cortex (Figure 4b) and
in hippocampus (Figure 4c). Our results suggest that HFD
damaged the synaptic plasticity and reduced the amount of
immature neuronal NSCs in the brain.
HFD attenuated the expression of TLX in the mouse
brain. To determine alterations in a differentiation and
proliferation-related transcription factor in the brain, we
checked the expression of tailless (TLX) in mice fed a HFD
(Figure 5). TLX immunoreactivity was reduced in the brain of
mice fed a HFD compared with that of the control animals
(Figure 5a). The protein level of TLX in the striatum, cortex,
and hippocampus of mice fed a HFD was attenuated
compared with that of the control mice (Figure 5b).
As several studies demonstrated that the TLX transcription
factor is related to self-renewal and neurogenesis of the
NSCs,48–50 our findings suggest that HFD reduces TLX
expression in the brain.
HFD reduced AdipoR1 expression. To assess the expres-
sion of AdipoR1 and AdipoR2 in the brain of mice fed a HFD,
we performed immunohistochemical analysis (Figures 6a
and c) and western blotting (Figures 6b and d) using specific
antibodies. Immunoreactivity for AdipoR1 in brain of mice
fed a HFD was decreased compared with that in the control
group (Figure 6a). Western blot experiments showed that
the protein level of AdipoR1 in the striatum, cortex, and
hippocampus was reduced in the HFD group (Figure 6b).
Immunoreactivity for AdipoR2 in HFD brain were reduced
compared with the control group (Figure 6c). The protein
levels of AdipoR2 in HFD brain were slightly attenuated in
Figure 1 Histological assessment of the brain of mice fed a high-fat diet (HFD) using cresyl violet staining. Cresyl violet staining revealed a slight cell loss in the cortex and
striatum of mice fed a HFD (b), whereas cells in the control group had more healthy and round cell bodies in the cortex and striatum (a). Scale bar: 200 and 50 μm. Control: control
group; HFD: high-fat diet group
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comparison with the control group brain (Figure 6d).
Our findings suggest that HFD decreases AdipoR
expression, and attenuates the AdipoR-mediated signaling
in the brain.
Adiponectin maintains the neurosphere size of NSCs at
high glucose concentrations in vitro. We investigated
whether neurosphere size of NSCs was changed by
adiponectin at high glucose concentrations (Figure 7). Neuro-
sphere size was measured using bright-field microscopy
(Figure 7a). Neurosphere size was not altered by the
adiponectin (Acrp30, 30 μg/ml) treatment, and was similar
to that in the control group. A treatment with 120mM glucose
reduced the neurosphere size compared with that in the
control group. However, addition of Acrp30 (30 μg/ml) and
120mM glucose did not alter neurosphere size compared
Figure 2 Measurement of cell damage using the TUNEL assay. (a) TUNEL-positive signal (green), which indicates cells with DNA damage, was increased in the brain of mice
fed a high-fat diet (HFD). (b) Similarly, TUNEL signal was increased in the cortex, striatum, and hippocampus in the HFD group compared with that in the control group. (c) NeuN
(red)-positive cells were decreased in the HFD brain striatum and hippocampus. TUNEL (green)- and NeuN (red)-positive signals were also increased in the HFD brain compared
with the control group. Scale bar: 200 μm. Control: control group, HFD: high-fat diet group. 4',6-diamidino-2-phenylindole (DAPI): blue; TdT-mediated dUTP nick end labeling
(TUNEL): green; NeuN: red. *Po0.05, **Po0.001
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with that in the control group (Figures 7a and b). Especially,
120mM glucose group showed significant differences with
the control group (Figure 7b). Therefore, our data showed
that adiponectin helps to maintain the normal size of NSC
neurospheres at high glucose concentration.
Adiponectin restored the reduced expression of AdipoR1
in the NSCs caused by high glucose concentrations. To
examine AdipoR1 and AdipoR2 expression in the NSCs at
high glucose concentrations, we conducted reverse transcrip-
tion PCR (Figure 8a), quantitative PCR (Figures 8b and c) and
Figure 3 Measurement of PSD95 expression in the brain of mice fed a high-fat diet (HFD). (a) Immunohistochemical experiments revealed that the PSD95-positive
immunostaining (green) was attenuated in the brain of mice fed a HFD. In addition, PSD95 immunoreactivity was reduced in the striatum, cortex, and hippocampus of the HFD
group compared with those of the control group. Scale bar: 200 μm. 4',6-diamidino-2-phenylindole (DAPI): blue; postsynaptic density protein 95 (PSD95): green. (b) The protein
level of PSD95 was significantly reduced in the HFD group compared with that in the control group. β-Actin was used as internal control. Data are expressed as mean±S.E.M.,
and each experiment included three repeats per condition. Differences were considered significant at *Po0.05. Control: control group; HFD: high-fat diet group
Figure 4 Measurement of DCX expression in the brain of mice fed a high-fat diet (HFD). (a) Immunohistochemical experiments revealed that the DCX-immunopositive signal
(green) was reduced in the brain of mice fed a HFD. In addition, DCX immunoreactivity was decreased in the striatum, cortex, and hippocampus of the HFD group compared with
those of the control group. Scale bar: 200 μm. 4',6-diamidino-2-phenylindole (DAPI): blue; doublecortin (DCX): green. (b) The protein level of DCX was significantly reduced in the
HFD brain cortex compared with that in the control group. β-Actin was used as internal control. Data are expressed as mean±S.E.M., and each experiment included four repeats
per condition. Differences were considered significant at *Po0.05. (c) The protein level of DCX was a little decreased in the HFD brain hippocampus in comparison with the
control group. β-Actin was used as internal control. Data are expressed as mean± S.E.M., and each experiment included four repeats per condition. Differences were considered
significant at *Po0.05. Control: control group; HFD: high-fat diet group
Figure 6 Measurement of AdipoR1 and AdipoR2 expression in the brain of mice fed a high-fat diet (HFD). (a) Immunohistochemical experiments revealed that the AdipoR1-
positive immunolabeling (red) was attenuated in the brain of mice fed a HFD. In addition, AdipoR1 immunoreactivity was reduced in the striatum, cortex, and hippocampus of the
HFD group compared with those of the control group. Scale bar: 200 μm. 4',6-diamidino-2-phenylindole (DAPI): blue; AdipoR1: red. (b) Western blotting experiments showed that
the relative protein level of AdipoR1 was reduced in the HFD group compared with that in the control group. β-Actin was used as internal control. Data are expressed as mean
± S.E.M., and each experiment included three repeats per condition. Differences were considered significant at *Po0.05. (c) Immunohistochemical experiments revealed that
the AdipoR2-positive immunolabeling (green) was attenuated in the brain of mice fed a HFD. In addition, AdipoR2 immunoreactivity was reduced in the striatum, cortex, and
hippocampus of the HFD group compared to those of the control group. Scale bar: 200 μm. 4',6-diamidino-2-phenylindole (DAPI): blue; AdipoR2: green. (d) Western blotting
experiments showed that the relative protein level of AdipoR2 was slightly reduced in the HFD group compared with that in the control group. β-Actin was used as internal control.
Data are expressed as mean± S.E.M., and each experiment included three repeats per condition. Differences were considered significant at *Po0.05. Control: control group;
HFD: high-fat diet group
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Figure 5 Measurement of TLX expression in the brain of mice fed a high-fat diet (HFD). (a) Immunohistochemical experiments revealed that the TLX-positive immunostaining
(green) was attenuated in the brain of mice fed a HFD. In addition, TLX immunoreactivity was reduced in the striatum, cortex, and hippocampus of the HFD group compared with
those in the control group. Scale bar: 200 μm. 4',6-diamidino-2-phenylindole (DAPI): blue; TLX: green. (b) The protein level of TLX was reduced in the HFD group compared with
that in the control group. β-Actin was used as internal control. Data were expressed as mean±S.E.M., and each experiment included four repeats per condition. Differences were
considered significant at **Po0.001. Control: control group; HFD: high-fat diet group
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immunohistochemical analysis (Figure 8d). At 120mM
glucose concentration, mRNA level of AdipoR1 in the NSCs
was attenuated compared with that in the control group,
whereas Acrp30 (30 μg/ml) treatment restored the mRNA
level of AdipoR1 reduced by high glucose concentrations
(Figures 8a and b). At 120mM glucose concentration, mRNA
level of AdipoR2 in the NSCs was slightly attenuated
compared with that in the control group, whereas Acrp30
(30 μg/ml) treatment increased the mRNA level of AdipoR2.
Acrp30 treatment did not largely increase the expression
of AdipoR2 in high glucose concentrations (Figure 8c).
In addition, we observed less AdipoR1 and DCX immunor-
eactivity in the NSCs exposed to high glucose concentration
than in the control group (Figure 8d). However, the decreased
immunoreactivity of AdipoR1 and DCX was enhanced by
Acrp30 (30 μg/ml) treatment at high glucose concentrations
(Figure 8d). Taken together, adiponectin may promote the
expression of AdipoR1 and DCX in the NSCs exposed to high
glucose concentrations.
Adiponectin inhibits the pathways responsible for
apoptosis in the NSCs at high glucose concentrations.
To investigate the effect of adiponectin on the apoptosis
signaling pathways at high glucose concentrations, we
measured the mRNA level of the apoptosis-related factors
p21, p53, and c-Myc51–53 (Figure 9). Blocking AdipoR1 using
AdipoR1 blocker compound increases the mRNA levels of
p21 (Figure 9a), p53 (Figure 9b), and c-Myc (Figure 9c) in the
NSCs compared with the Acrp30 (30 μg/ml) treatment.
The mRNA levels of p21, p53, and c-Myc in the NSCs
were significantly reduced by treatment with both Acrp30
(30 μg/ml) and glucose (120mM) compared with treatment
with glucose only (Figures 9d–f). We propose that adiponec-
tin may inhibit the apoptosis pathways mediated by p21/p53
and c-Myc at high glucose concentrations.
Adiponectin enhances neurogenesis and proliferation in
the NSCs at high glucose concentrations. To study the
effect of adiponectin on the neurogenesis and proliferation of
NSCs at high glucose concentrations, we measured the
mRNA levels of the neuronal cell factor DCX and the
proliferation and neurogenesis-related factor TLX
(Figure 10). Acrp30 (30 μg/ml) increased the mRNA levels
of DCX (Figure 10a) and TLX (Figure 10b) in the NSCs.
In addition, under Acrp30 (30 μg/ml) with 120mM glucose
condition, the mRNA levels of DCX (Figure 10a) and TLX
(Figure 10b) increased compared with the glucose treatment
group (Figures 10a and b). We observed a decrease in
neurosphere size by inhibiting TLX using siTLX, and an
increase in neurosphere size by Acrp30 (30 μg/ml) treatment
(Figures 10c and d). Expressions of DCX and TLX in the
NSCs were increased by TLX inhibition (Figures 10e and f).
These data suggest that adiponectin might promote the
neurogenesis related to DCX and TLX in the NSCs at high
glucose concentrations.
Discussion
Current research reports a positive correlation between DM2
and cognitive impairment in a prospective population-based
study,54 and an accelerated progression from mild cognitive
decline to dementia in the elderly patients with DM2 compared
with the normal subjects.55 In addition, patients with diabetes
(35%) or glucose intolerance (46%) have Alzheimer’s disease
in up to 80% of patients.56 Hyperglycemia is a main cause
of neuronal damage, leading to neurodegeneration in the
CNS.57–60 Cognitive impairment in DM2 generally affects the
brain regions responsible for learning and memory.38,61
Patients with DM2-induced dementia have mitochondrial
dysfunction and alterations in the neuronal synapses.62–64
Considering that the number of unhealthy and TUNEL-positive
cells, which are considered as apoptotic,65 was increased in
the brain of mice fed a HFD, we suggest that HFD leads to
Figure 7 Measurement of neurosphere size at high glucose concentration.
(a) Neurospheres were observed using bright-field microscopy, and neurosphere size
was measured using the Image J (Madison, Wisconsin, USA). Size of neurospheres
was identical in the Acrp30 treatment and the control groups. Glucose treatment
reduced the neurosphere size compared with the control group. Glucose and Acrp30
treatment increased the size of neurospheres compared with the glucose treatment
only. Scale bar: 200 μm. Normal: control group; Glu (90 mM): 90 mM glucose
treatment group; Glu (120 mM): 120 mM glucose treatment group; Acrp30: Acrp30
(30 μg/ml) treatment group. (b) The graph showed the size of neurospheres in each
group. In 90 and 120 mM glucose group, neurosphere size was attenuated in
comparison with the normal control group. Under Acrp30 treatment, the
neurospheres were increased compared with the glucose treatment only.
*Po0.05, **Po0.001
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cellular damage in the brain. In addition, reduction of the
postsynaptic protein PSD95, which is associated with
memory,66 suggests that HFD impairs synaptic plasticity.
Memory dysfunction in type II diabetes mellitus67 triggers
neuronal death and inhibits neurogenesis.40,68,69 In addition,
HFD accelerates the progression of diabetes and inhibits
neurogenesis in rodents.70 Patients with DM2 have decreased
adiponectin plasma levels compared with normal subjects.71
In an animal study of DM2, decreased adiponectin level was
considered the reason for the higher prevalence of insulin
resistance.72 In the present study, we observed the decrease
of AdipoR1 receptor 13,73–76 in various brain regions including
the striatum, cortex, and hippocampus compared with the
control group; however, we did not measure the plasma levels
of adiponectin in the mice fed a HFD.
Recent studies demonstrated that HFD induces synaptic
dysfunction77 and leads to neurotoxicity in vivo.78 Our results
showed that the mRNA levels of p21, p53, and cMyc in the
NSCs were increased at high glucose concentrations,
whereas these effects were attenuated by adiponectin. The
protein p53 triggers apoptosis,79,80 inhibits self-renewal,
induces the differentiation of embryonic stem cells,81 and
blocks the reprogramming of progenitor cells into stem
cells.82,83 The activation of p53 and p21 indicates DNA
damage in stem cells.84–88 In addition, the activation of
p53/p21 signaling leads to cell arrest in the G1 and G2 phases
of the cell cycle, and thus apoptosis.89,90 Recent studies
demonstrated that the increased apoptosis of NSCs through
p53 and p21 inhibits proliferation.84,91 Proliferation of bone
marrow-derived stem cells is blocked by activating the cell
cycle inhibitors p53 and p21.92 In an animal study investigating
diabetes, the activation of p21 triggered the apoptosis of bone
marrow-derived mesenchymal stem cells.93 In addition, p53
induces the transduction of c-Myc94,95 and thus regulates
Figure 8 Measurement of AdipoR1 and AdipoR2 expression in the NSCs. The mRNA level of AdipoR1 (a and b) and AdipoR2 (c) was measured with reverse transcription
PCR (a) and quantitative PCR (b and c). (a and b) Glucose treatment (120 mM) reduced the mRNA level of AdipoR1 compared with the control group. Glucose and Acrp30
treatments in combination increased the mRNA level of AdipoR1 compared with the glucose treatment. Data are expressed as mean± S.E.M., and each experiment included
three repeats per condition. GAPDH was used as control gene. Differences were considered significant at *Po0.05 and **Po0.001. (c) Glucose treatment (120 mM) slightly
reduced the mRNA level of AdipoR2 compared with the control group. Glucose and Acrp30 treatments in combination was not increased the mRNA level of AdipoR2 compared
with the glucose treatment. Data are expressed as mean± S.E.M., and each experiment included three repeats per condition. GAPDH was used as control gene. Differences
were considered significant at *Po0.05. (d) Immunohistochemical experiments revealed that the expression of AdipoR1 (green) was reduced in the glucose treatment group
compared with that in the control group. Treatment with both glucose and Acrp30 increased AdipoR1 expression compared with the glucose treatment. Scale bar= 200 μm.
4',6-diamidino-2-phenylindole (DAPI): blue; adiponectin receptor 1 (AdipoR1): green; DCX: red
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various mechanisms such as apoptosis,96 cell growth,97 and
self-renewal of embryonic stem cells.98 As the increase of p21,
p53, and c-Myc induces apoptosis,52,99–101 our results imply
that adiponectin protects against cell death of NSCs during
glucose-induced toxicity. In the present study, we showed that
HFD attenuated the expression of DCX and TLX neurogen-
esis markers in the brain. The nuclear receptor TLX is required
for neurogenesis in the subventricular zone.102,103 Several
studies reported that this orphan nuclear receptor increases
the self-renewal of NSCs104–107 and promotes the neurogen-
esis of neural precursor cells.50,108–111 TLX-positive cells are
associated with learning and memory.105 Similarly, the
neurogenesis-related protein DCX112,113 is crucial for learning
and memory,114–117 and is involved in synaptic
dysfunction.118–120 Our results showed that adiponectin
increases the expression of TLX and DCX in the NSCs at
high glucose concentrations, and that blocking AdipoR1
reduces TLX expression in the NSCs. Furthermore, the
blockade of TLX did not change the size of neurospheres,
and adiponectin treatment increased TLX expression.
In conclusion, our findings in the present study suggest the
following. Considering our in vivo results, HFD might lead to
the reduction of AdipoR1 that is related to cell survival,121–123
impaired synaptic plasticity,124–126 and attenuation of
neurogenesis.112,127 Considering our in vitro results,
AdipoR1-mediated signaling might protect the NSCs against
cell damage at high glucose concentrations, and might
promote the self-renewal and neurogenesis of the NSCs at
high glucose concentrations. The lack of clinical data is a
limitation of this study. However, as our study has indicated the
potential of adiponectin to alleviate hyperglycemia-induced
neuropathogenesis, our results might spark further studies
investigating adiponectin receptor signaling in the CNS.
Materials and Methods
Animal experiments. Male 3-week-old C57BL/6 mice (Orient, GyeongGi-Do,
South Korea; http://www.orientbio.co.kr) were fed conventional chow or HFD; the
latter was enriched in either fat (35.5% wt/wt; Bioserv, Frenchtown, NJ, USA) or
fructose (60% wt/wt; Harlan Teklad, Madison, WI, USA) for 4 weeks. Then, animals
on the HFD were injected once with streptozotocin (STZ; 100 mg/kg body weight;
Sigma-Aldrich, St. Louis, MO, USA) intraperitoneally to induce partial insulin
deficiency, and then the HFD was continued for an additional 4 weeks. The majority
of mice in the STZ/HFD group exhibited hyperglycemia, insulin resistance, and
glucose tolerance, as previously reported.128 The mice that were fed conventional
chew (control group) were injected intraperitoneally with vehicle (0.05 mol/l citric
acid, pH 4.5). To obtain their brains, mice were killed under ether anesthesia.
Cresyl violet staining. After the mice were killed, their brains were fixed in
3.7% formaldehyde and immediately frozen. The brains were sectioned coronally at
a thickness of 20 μm, and the sections were sequentially incubated in xylene for
4 min, 100% alcohol for 5 min, 95% alcohol for 5 min, and 70% alcohol for 5 min.
Samples were stained with cresyl violet (Sigma-Aldrich) for 5 min. After the staining,
slides were dehydrated with 70% alcohol for 3 min, 95% alcohol for 3 min, 100%
alcohol for 3 min, and xylene for 5 min. Sections were observed using a light
microscope equipped with a digital camera (Olympus, Tokyo, Japan).
Figure 9 Measurement of mRNA levels in the NSCs using reverse transcription PCR. The mRNA levels of p21 (a and d), p53 (b and e), and c-Myc (c and f) in the NSCs were
evaluated using reverse transcription PCR. Acrp30 (30 μg/ml) treatment reduced the mRNA levels of p21 (a), p53 (b), and c-Myc (c) in the NSCs compared with the blocking of
AdipoR1. The mRNA levels of p21 (d), p53 (e), and c-Myc (f) in the NSCs were reduced upon treatment with both glucose and Acrp30 (30 μg/ml) compared with those treated
with glucose. Data are expressed as mean± S.E.M., and each experiment included three repeats per condition. GAPDH was used as control gene. Differences were considered
significant at *Po0.05 and **Po0.001
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TdT-mediated dUTP nick end labeling. Apoptotic cells were detected
in situ using the Roche TUNEL kit (Roche, Mannheim, Germany) according to the
manufacturer’s protocol. The TUNEL assay was conducted to visualize the 3'-OH
ends of DNA fragments in apoptotic cells. After xylene dewaxing, sections were
rinsed three times in distilled water for 5 min, and they were washed in methanol
containing 0.3% H2O2 at room temperature for 30 min to inhibit endogenous
peroxidase activity. After rinsing in PBS three times at room temperature for 5 min,
sections were treated with proteinase K at 37 °C for 6 min. Section were rinsed in
PBS three times at room temperature for 3 min, were soaked in TdT buffer for
10 min, and incubated in 50 μl TdT buffer containing TdT at 37 °C for 60 min in a
moist chamber (Roche). After three rinsing steps in PBS at room temperature for
5 min, the sections were incubated in 50 μl FITC (Roche) at 37 °C for 40 min. After
three further rinses in PBS for 3 min, the brain sections were incubated in DAB
(Roche) at room temperature for 3 min, and the signal was observed using a
confocal microscope (Zeiss LSM 700, Carl Zeiss, Oberkochen, Germany).129
Immunohistochemistry of the sections. Frozen brain sections, 5 μm
thick, were cut onto clean glass slides (Thermo Scientific, Waltham, MA, USA),
air-dried, and fixed in cold acetone for 10 min at − 20 °C. The slides were washed in
Tris-buffered saline (TBS), and then incubated in 0.3% H2O2 in methanol to quench
endogenous peroxidase activity. Followed by three washes in distilled water, the
sections were blocked with 10% normal rabbit serum. To block nonspecific labeling,
sections were incubated in 5% bovine serum albumin (BSA, Sigma-Aldrich) diluted
in PBS for 30 min before the addition of primary and secondary antibodies. Sections
were incubated with primary antibodies specific for AdipoR1 (1 : 100, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), DCX (1 : 100, Abcam, Cambridge, MA,
USA), NeuN (1 : 100, Abcam), PSD95, 1 : 100, Millipore, Billerica, MA, USA), and
orphan factor tailless (TLX, 1 : 100, Santa Cruz Biotechnology) for 24 h at 4 °C and
then washed in PBS for 10 min. After three washes in 0.1% PBS with Tween-20
(PBST), sections were incubated for 2 h in the dark at room temperature with
rhodamine-conjugated sheep anti-rabbit or fluorescein isothiocyanate (FITC)-
Figure 10 Measurement of DCX and TLX expression in the NSCs. The mRNA levels of DCX (a) and TLX (b) in the NSCs were evaluated using quantitative PCR. Treatment
with both glucose and Acrp30 (30 μg/ml) increased the mRNA levels of DCX (a) and TLX (b) compared with the glucose treatment only. (c and d) Neurosphere size was reduced
by using siTLX, but Acrp30 (30 μg/ml) treatment slightly increased neurosphere size. Data are expressed as mean±S.E.M., and each experiment included three repeats per
condition. GAPDH was used as control gene. Differences were considered significant at *Po0.05. Blocking TLX significantly increased the mRNA levels of DCX (e) and TLX
(f) in the NSCs treated with Acrp30 (30 μg/ml). Data are expressed as mean± S.E.M., and each experiment included three repeats per condition. GAPDH was used as control
gene. Differences were considered significant at *Po0.05 and **Po0.001
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conjugated sheep anti-mouse secondary antibodies that were diluted to 1 : 200 with
5% BSA in 0.1% PBST. After three washes in PBS, sections were incubated in 1 μg/ml
4′,6-diamidino-2-phenylindole (Sigma-Aldrich) and 2 μg/ml propidium iodide
(Sigma-Aldrich) as a counterstain. Sections were observed using a confocal
microscope (Zeiss LSM 700, Carl Zeiss, Oberkochen, Germany).
NSC primary culture and drug treatment. Pregnant ICR mice were
killed to obtain cortical primary NSCs according to a previously described
method.130 The brains were extracted from E13.5 embryos, and placed in a Petri
dish containing Hank’s balanced salt solution (HBSS, Gibco, Grand Island, NY,
USA). The cortices were dissected and washed 1–2 times with HBSS. To each
piece of washed tissue, 5 ml HBSS was added, and the tissue was dissociated by
pipetting up and down. Tissues were triturated by repeated passages through a fire-
polished constricted Pasteur pipette. Dissociated tissues were allowed to settle for
3 min. Supernatants were transferred to a fresh tube, and were centrifuged at
1200 × g for 3 min. Pellets were resuspended in NSC basal media with a
proliferation supplement (Stem Cell Technologies, Vancouver, BC, Canada), and
20 ng/ml epidermal growth factor (EGF, Invitrogen, Carlsbad, CA, USA). Live,
Trypan blue-negative cells were counted. NSCs were plated on poly-D-ornithine
(Sigma-Aldrich)-treated plastic dishes at a density of 2.5 × 104 cells per ml. Cultures
were maintained in a humidified atmosphere of 95% air and 5% CO2 at 37 °C. After
3 days in vitro, the cells proliferated and formed primary neurospheres. The primary
neurospheres were harvested by centrifugation, and were dissociated to single cells
using Accumax (Sigma-Aldrich). The single cells were seeded on culture plates
coated with 0.001% poly-L-ornithine. Culture medium was replaced every 3 days.
NSCs were used for experiments after 2–3 passages.131 NSCs were exposed to
Acrp30 (30 μg/ml, Sigma-Aldrich) for 4 days after 2–3 passages. Subsequently,
cells were exposed to D-glucose The cells were also treated with the AdipoR1
blocking peptide (3 μg/ml, GTX89569-PEP, GeneTex, Irvine, CA, USA) for 4 days of
the experiment.132
TLX silencing treatment. For the transfection, siRNA TLX (20 nM final
concentration, Ambion, Austin, TX, USA) in Opti-MEM was mixed with
Lipofectamine 2000 (Invitrogen) and incubated at room temperature for 10 min.
The mixture was then added to the NSCs that incubated in the mixture for 72 h.
Quantification of neurosphere size. Neurospheres were imaged using a
bright-field inverted microscope (Olympus). The magnification (×10) covered a
significant area of each well from the 24-well plates. Ten non-overlapping fields were
selected randomly from each well. All experiments were carried out 6 times.
Reverse transcription PCR. To examine the expression of AdipoR1, c-Myc,
p21, p53, DCX, and TLX in the NSCs, reverse transcription PCR was performed to
measure their mRNA levels. Briefly, cells were lysed with Trizol reagent (Invitrogen),
and total RNA was extracted according to the manufacturer’s protocol. We
synthesized cDNA from the mRNA. The following cycling conditions were used for
the PCR: 10 min at 95 °C; 35 cycles of denaturing at 95 °C for 15 s, annealing for
30 s at 62 °C, elongation at 72 °C for 30 s; final extension for 10 min at 72 °C. PCR
was performed using the following primers (5' to 3'): AdipoR1 (F): GAGCATCTTCC
GCATTCATA, (R): AAGAGCCAGGAGAAGCTGAG; c-Myc (F): TCAAGAGGCGAAC
ACACAAC, (R): GGCCTTTTCATTGTTTTCCA; p21 (F): AGTGTGCCGTTGTCTCT
TCG, (R): ACACCAGAGTGCAAGACAGC; p-53 (F): CTGCCCTCAACAAGATGTT
TTG, (R): CTATCTGAGCAGCGCTCATGG; TLX: (F): GGCTCTCTACTTCCGTG
GACA, (R): GTCAGTATTCATGCCAGATACAGCCAGTG; DCX (F): AATCCCAACTG
GTCTGTCAAC, (R): GTTTCCCTTCATGACTCGGCA; GAPDH (F): GGCATGGACT
GTGGTCATGAG, (R): TGCACCACCAACTGCTTAGC. We examined the PCR
products with electrophoresis using 1.5% agarose gels stained with ethidium
bromide.
Quantitative real-time PCR. To examine the amount of AdipoR1, DCX, and
TLX mRNAs in the NSCs, we performed quantitative real-time PCR. Total RNA was
extracted from the NSCs using the Trizol reagent (Invitrogen) according to the
manufacturer’s instructions. RNA was mixed with the One Step SYBR Prime Script
TM RT-PCR Kit II (Takara, Otsu, Shiga, Japan) and the specific primers in 20 μl total
reaction volume. PCR was performed using the following primers (5′ to 3′); AdipoR1
(F): GAGCATCTTCCGCATTCATA, (R): AAGAGCCAGGAGAAGCTGAG; AdipoR2
(F): TGTTCGCCACCCCTCAGTAT, (R): AATGATTCCACTCAGGCCCA, TLX (F):
GGCTCTCTACTTCCGTGGACA, (R): GTCAGTATTCATGCCAGATACAGCCAGTG;
DCX (F): AATCCCAACTGGTCTGTCAAC, (R): GTTTCCCTTCATGACTCGGCA;
GAPDH (F): GGCATGGACTGTGGTCATGAG, (R): TGCACCACCAACTGCTTAGC.
The PCR was performed at 42 °C for 5 min, 95 °C for 10 s, followed by 40 cycles of
95 °C for 15 s, 60 °C for 34 s, and 65 °C for 15 s. Quantitative PCR was performed
with the ABI prism 7500 Real-Time PCR System (Life Technologies, Grand Island,
NY, USA), and we analyzed the Ct values using relative quantification.
133 Data were
normalized to the reference housekeeping gene GAPDH. The ΔCt values of the
treated cells were compared with those of the untreated cells.
Western blot analysis. Cells were washed rapidly with ice-cold PBS,
scraped, and collected. Cell pellets were lysed with ice-cold RIPA buffer (Sigma-
Aldrich). Lysates were centrifuged at 13 000 r.p.m. for 1 h at 4 °C to produce whole-
cell extracts. Protein content was quantified using the BCA kit (Pierce, Rockford, IL,
USA). Proteins (40 μg) were separated on a 10% sodium dodecyl sulfate-
polyacrylamide gel and then transferred onto a polyvinylidene difluoride membrane.
After blocking with 5% BSA in Tris-buffered saline/Tween (TBS-T; 20 nM Tris
(pH 7.2), 150 mM NaCl, and 0.1% Tween-20) for 1 h at room temperature,
immunoblots were incubated overnight at 4 °C with the primary antibodies specific
for PSD95 (1 : 1000, Millipore), DCX (1 : 1000, Abcam), TLX (1 : 1000, Santa Cruz
Biotechnology), AdipoR1 (1 : 1000, Santa Cruz Biotechnology), AdipoR2 (1 : 1000,
Santa Cruz Biotechnology), and β-actin (1 : 2000, Cell Signaling Technology,
Danvers, MA, USA). Next, the blots were incubated with horseradish peroxidase-
linked anti-mouse and anti-rabbit IgG antibodies (Abcam) for 1 h at room
temperature. Chemiluminescence signal was developed using an ECL kit
(Invitrogen).
Immunocytochemistry of the NSCs. NSCs were washed three times with
PBS, and were permeabilized for 30 min. NSCs were incubated with the primary
antibodies overnight at 4 °C. The following primary antibodies were used: anti-goat
AdipoR1 (1 : 200, Santa Cruz Biotechnology) and anti-rabbit DCX (1 : 200, Abcam).
The primary antibody was then removed, and the cells were washed three times for
3 min with PBS. Cells were incubated with FITC-conjugated donkey anti-goat IgG
(1 : 200, Jackson Immunoresearch, West Grove, PA, USA), and rhodamine-
conjugated goat anti-rabbit IgG (1 : 200, Jackson Immunoresearch) for 2 h at room
temperature. NSCs were washed again three times for 3 min with PBS. NSCs were
then counterstained with 1 μg/ml 4',6-diamidino-2-phenylindole (DAPI, 1 : 200,
Invitrogen) for 10 min at room temperature. Cells were imaged using a Zeiss LSM
700 confocal microscope (Carl Zeiss, Thornwood, NY, USA).
Statistical analysis. Statistical analyses were carried out using the SPSS
18.0 software (IBM Corporation, Armonk, NY, USA). All data are expressed as
mean± S.E.M. Significant intergroup differences were determined by one-way
analysis of variance (ANOVA) followed by the Bonferroni post hoc multiple
comparison test. Each experiment included three replicates per condition.
Differences were considered significant at *Po0.05 and **Po0.001.
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